State Street’s Lexeo Therapeutics LXEO Stock Holding History

State Street’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.5M	Buy	3,568,242 +380,520	+12%	+$2.7M	﹤0.01%	2224
2025 Q4	$31.7M	Buy	3,187,722 +2,642,877	+485%	+$24.1M	﹤0.01%	2004
2025 Q3	$3.62M	Buy	544,845 +31,819	+6%	+$154K	﹤0.01%	3123
2025 Q2	$2.06M	Buy	513,026 +43,298	+9%	+$142K	﹤0.01%	3305
2025 Q1	$1.63M	Buy	469,728 +12,325	+3%	+$54.6K	﹤0.01%	3315
2024 Q4	$3.01M	Buy	457,403 +203,457	+80%	+$1.6M	﹤0.01%	3175
2024 Q3	$2.3M	Buy	253,946 +57,674	+29%	+$688K	﹤0.01%	3280
2024 Q2	$3.15M	Buy	196,272 +84,057	+75%	+$1.22M	﹤0.01%	3123
2024 Q1	$1.76M	Buy	+112,215	New	+$1.75M	﹤0.01%	3321

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's LXEO Position: Q1 2026 in Review

State Street increased its Lexeo Therapeutics (LXEO) stake by 12% in Q1 2026, buying an estimated $2.7M and bringing the position to 3,568,242 shares worth $20.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2224.

State Street first reported a position in LXEO in Q1 2024 and has held it in 9 quarters since. The position peaked at $31.7M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

State Street held 3,568,242 shares of Lexeo Therapeutics worth $20.5M as of Q1 2026.
State Street bought 380,520 Lexeo Therapeutics shares in Q1 2026, an estimated $2.7M.
Lexeo Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2224 holding.
State Street first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 9 quarters since.
State Street's Lexeo Therapeutics position peaked at $31.7M in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.